Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2670 | Prone positioning (PP) Wiki | 0.71 |
| drug3897 | high flow nasal cannula (HFNC) Wiki | 0.71 |
| drug1030 | Dexamethasone Wiki | 0.24 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.13 |
| D055371 | Acute Lung Injury NIH | 0.13 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Description: A binary response, whereby a participant is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs ≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case.
Measure: To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age Time: 1 yearDescription: Incidence of adverse events. Incidence of serious adverse events, medically attended adverse events, and adverse events of special interest.
Measure: To assess the safety and tolerability of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age Time: a: 28 days post each dose of study Intervention. / b: from Day 1 post-treatment through Day 730.Description: Incidence of local and systemic solicited adverse events.
Measure: To assess the reactogenicity of 2 IM doses of AZD1222 compared to placebo in adults ≥ 18 years of age (Substudy only) Time: 7 days post each dose of study intervention.Description: Proportion of participants positive for SARS-CoV-2 Nucleocapsid antibodies over time.
Measure: To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of SARS-CoV-2 asymptomatic infection Time: 1 yearDescription: The incidence of the first case of SARS-CoV-2 RT-PCR positive symptomatic illness occurring ≥ 15 days post second dose of study intervention using CDC criteria
Measure: To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of symptomatic COVID-19 using CDC criteria Time: 1 yearDescription: The incidence of the first case of SARS-CoV-2 RT-PCR positive symptomatic illness occurring ≥ 15 days post second dose of study intervention using University of Oxford defined symptom criteria
Measure: To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of University of Oxford defined symptomatic COVID-19 Time: 1 yearDescription: The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring ≥ 15 days post second dose of study intervention.
Measure: To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of severe or critical symptomatic COVID-19 Time: 1 yearDescription: The incidence of COVID-19-related Emergency Department visits occurring ≥ 15 days post second dose of study intervention
Measure: To estimate the efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19-related Emergency Department visits Time: 1 yearDescription: Post-treatment GMTs and GMFRs in SARS-CoV-2S, RBD antibodies (MSD serology assay); The proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to the S, RBD antigens of AZD1222 (MSD serology assay)
Measure: To assess antibody responses to AZD1222 S antigen following 2 IM doses of AZD1222 or placebo (Substudy and Illness Visits only) Time: 28 days post each doseDescription: Post-treatment GMTs and GMFRs in SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay); Proportion of participants who have a post-treatment seroresponse (≥ 4-fold rise in titers) to AZD1222 as measured by SARS-CoV-2 neutralizing antibodies (wild-type assay or pseudo-neutralization assay)
Measure: To determine anti-SARS-CoV-2 neutralizing antibody levels in serum following 2 IM doses of AZD1222 or placebo (Sub-study and Illness Visits only) Time: 28 days post each doseThe purpose of this study is to evaluate safety and immunogenicity of AZD1222 for COVID-19 prevention in the Russian Federation
Description: Occurrence of SAEs following the first vaccination and throughout the study duration (Day 180).
Measure: Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability]. Time: 180 daysDescription: Local and systemic solicited AEs for 7 days following each vaccination. Unsolicited AEs for 28 days following each vaccination. Occurrence of AESIs following the first vaccination and throughout the study duration (Day 180).
Measure: Incidence of Solicited AEs for 7 following each vaccination [Safety and Tolerability]. Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: SARS-CoV-2 antigen-specific antibody levels Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: The rate of participants seroconverting from negative to positive SARS-CoV-2 S antigen Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: The rate of participants seroconverting from negative to positive SARS-CoV-2 N Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Quantity of SARS-CoV-2 neutralizing antibodies Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Count of peripheral blood mononuclear cells (PBMCs) Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Quantity of seasonal coronavirus antigens Time: 180 daysDescription: immunogenicity / serologic responses to AZD1222
Measure: Quantity of antibodies to the ChAdOx1vector and the persistence of these antibodies over time Time: 180 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports